|
MechanismH1 receptor antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date11 Sep 1951 |
100 Clinical Results associated with Taicang Shenzhou Biopharmaceutical Co., Ltd.
0 Patents (Medical) associated with Taicang Shenzhou Biopharmaceutical Co., Ltd.
100 Deals associated with Taicang Shenzhou Biopharmaceutical Co., Ltd.
100 Translational Medicine associated with Taicang Shenzhou Biopharmaceutical Co., Ltd.